20
Oct
2022

Bezos Bets on Fred Hutch, Prime Medicine Bucks the Trend, and PacBio Throws Down

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Merck Bets $10B on COPD, AbbVie Buys In Vivo CAR-T, & FDA Transparency
Avidity Advances in FSHD, Insmed Passes PAH Test, Merck Delivers with Oral PCSK9
Sanofi Buys Blueprint, BMS Antes for BioNTech Bispecific, & Kymera Degrader Delivers
GSK Antibiotic Hits, ORIC Prostate Cancer Drug Shines, & Taysha Goes 10-for-10